Export

EN
FR
Rifampicin
Essential medicine status
Section:
6. Anti-infective medicines 6.2. Antibacterials 6.2.4. Antileprosy medicines
ATC codes: J04AB02
EMLc
Indication
Leprosy ICD11 code: 1B50.Z
INN
Rifampicin
Medicine type
Chemical agent
Antibiotic groups
WATCH
List type
Core (EML)
(EMLc)
Additional notes
Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combination for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.
Formulations
Oral > Liquid: 20 mg per mL (EMLc)
Oral > Solid: 150 mg ; 300 mg
EML status history
First added in 1977 (TRS 615)
Changed in 1982 (TRS 685)
Changed in 2003 (TRS 920)
Changed in 2007 (TRS 950)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Rifampicin
DrugBank
Rifampicin
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of rifampicin oral liquid (20 mg/mL) to the EMLc.